2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4520 Persistent excess cardiovascular-kidney-metabolic-related mortality among adolescent and young adult survivors of hematologic malignancies

Husayn Mohamed Ladha, Hetty Carraway, MD, MBA2, Aaron T. Gerds, MD, MS3, Abhay Singh, MD, MPH4, Anjali Sunder Advani, MD5, Moaath Mustafa Ali, MD, MPH6, John Carlos Molina, MD, MEd7, Sophia Rebecca Balderman, MD8, Akriti G Jain, MD, FACP9, Faiz Anwer, MD10, Sudipto Mukherjee, MD, PhD, MPH11
1 Case Western Reserve University, Cleveland, Ohio, United States
2 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States
3 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States
4 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States
5 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States
6 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States
7 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States
8 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States
9 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States
10 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States
11 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States, Population Cancer Analytics Shared Resource, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Background: Improved survival among adolescent and young adult (AYA) cancer patients has shifted attention toward long-term treatment-related mortality. Given the shared pathophysiology and frequent coexistence of cardiovascular, kidney, and metabolic (CKM) diseases following cancer therapy, CKM mortality offers a more clinically meaningful and comprehensive measure of long-term survivorship than evaluating individual causes of death separately. We evaluated hematologic malignancy (HM)-specific excess CKM mortality in AYA survivors of HMs.

Methods: Population-based cancer registry data from the SEER 17 Research Plus database were used to identify patients aged 15–39 years with a first primary HM diagnosed between 2001 and 2023 who survived at least 1 year after diagnosis. HMs included acute leukemias (AL: acute lymphoblastic or acute myeloid leukemia), chronic myeloid leukemia (CML), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL). Chronic lymphocytic leukemia and multiple myeloma were excluded because of their low incidence in the AYA population. CKM deaths were defined as deaths attributed to diabetes mellitus, heart disease, hypertension, cerebrovascular disease, atherosclerotic or other arterial disease, or kidney disease. Standardized mortality ratios (SMRs) compared observed CKM deaths with expected deaths in the US general population, adjusted for age, sex, race/ethnicity, and calendar year of diagnosis. HM-specific Poisson models used log(expected deaths) as an offset and were adjusted for sex, race/ethnicity, age at diagnosis, time-dependent latency (12–59, 60–119, and ≥120 months); and diagnosis eras (2001–2005, 2006–2010, 2011–2015, and 2016–2023). Cumulative incidence functions treated cancer and other deaths as competing events and were estimated among survivors of at least 1 year and 5 years. Fine–Gray competing risk regression models were adjusted for sex, race/ethnicity, age at diagnosis, malignancy, and diagnosis era. Analyses were conducted in R 4.2.2 and SAS 9.4.

Results: Among 56,539 AYA survivors contributing 511,499 person-years, 460 CKM deaths occurred. CKM mortality was elevated for all HMs combined (SMR, 2.19; 95% CI, 1.99–2.40) and for each HM subtype: AL, 3.45 (95% CI, 2.69–4.36); HL, 2.18 (1.86–2.54); CML, 2.01 (1.38–2.82); and NHL, 1.96 (1.70–2.26). In adjusted Poisson models, CKM mortality did not differ significantly across diagnosis eras (P values: AL, .631; CML, .794; HL, .065; NHL, .112). Sensitivity analyses restricted to 12–59 months of follow-up and analyses censoring follow-up before the COVID-19 pandemic similarly showed no significant differences across diagnosis eras. At 20 years after diagnosis among ≥1-year survivors, the cumulative incidence of CKM death was 1.7% (95% CI, 1.2%–2.3%) for AL, 2.0% (1.2%–3.0%) for CML, 1.9% (1.6%–2.3%) for HL, and 2.0% (1.7%–2.4%) for NHL. Corresponding cumulative incidences of cancer death were 29% (95% CI, 28%–30%), 15% (13%–17%), 6.8% (6.4%–7.3%), and 10% (10%–11%), respectively. Among 5-year survivors, the 20-year cumulative incidence of CKM death was similar across HMs: 1.8% (1.2%–2.6%) for AL, 1.9% (1.1%–3.0%) for CML, 1.9% (1.6%–2.3%) for HL, and 1.9% (1.5%–2.3%) for NHL. Corresponding cumulative incidences of cancer death among 5-year survivors were 7.9% (6.9%–8.9%), 9.5% (8.0%–11%), 3.8% (3.4%–4.3%), and 4.7% (4.2%–5.2%), respectively. In Fine–Gray analyses, the adjusted subdistribution hazard of CKM death was higher among male survivors (sHR, 1.68; 95% CI, 1.38–2.04; P<.001), non-Hispanic Black survivors compared with non-Hispanic White survivors (sHR, 2.20; 1.74–2.80; P<.001), and survivors aged 35–39 years compared with those aged 15–19 years at diagnosis (sHR, 4.03; 2.72–5.96; P<.001). Compared with NHL, adjusted CKM subdistribution hazards did not differ significantly for AL, CML, or HL (all P≥.46).

Conclusions: AYA survivors of HMs experienced persistently elevated CKM mortality compared with the general population, with no significant variation across diagnosis eras. Long-term CKM mortality was similar across AL, CML, HL, and NHL, suggesting a shared survivorship burden rather than a diagnosis-specific late effect. Higher CKM risk among male, non-Hispanic Black, and older AYA survivors supports risk-adapted prevention, early cardiometabolic and kidney risk assessment, and longitudinal survivorship surveillance.

Husayn Mohamed Ladha: No relevant conflicts of interest to declare.